CAR-NK cells: A promising cellular immunotherapy for cancer
© 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies,...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier BV
2021
|
| Online Access: | https://hdl.handle.net/1721.1/135407 |
| _version_ | 1826195141555126272 |
|---|---|
| author | Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu |
| author_facet | Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu |
| author_sort | Xie, Guozhu |
| collection | MIT |
| description | © 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for ‘off-the-shelf’ manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer. |
| first_indexed | 2024-09-23T10:07:57Z |
| format | Article |
| id | mit-1721.1/135407 |
| institution | Massachusetts Institute of Technology |
| language | English |
| last_indexed | 2024-09-23T10:07:57Z |
| publishDate | 2021 |
| publisher | Elsevier BV |
| record_format | dspace |
| spelling | mit-1721.1/1354072021-10-28T04:34:46Z CAR-NK cells: A promising cellular immunotherapy for cancer Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu © 2020 The Author(s) Natural Killer (NK) cells and CD8+ cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for ‘off-the-shelf’ manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer. 2021-10-27T20:23:21Z 2021-10-27T20:23:21Z 2020 2021-07-15T15:35:38Z Article http://purl.org/eprint/type/JournalArticle https://hdl.handle.net/1721.1/135407 en 10.1016/J.EBIOM.2020.102975 EBioMedicine Creative Commons Attribution-NonCommercial-NoDerivs License http://creativecommons.org/licenses/by-nc-nd/4.0/ application/pdf Elsevier BV Elsevier |
| spellingShingle | Xie, Guozhu Dong, Han Liang, Yong Ham, James Dongjoo Rizwan, Romee Chen, Jianzhu CAR-NK cells: A promising cellular immunotherapy for cancer |
| title | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_full | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_fullStr | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_full_unstemmed | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_short | CAR-NK cells: A promising cellular immunotherapy for cancer |
| title_sort | car nk cells a promising cellular immunotherapy for cancer |
| url | https://hdl.handle.net/1721.1/135407 |
| work_keys_str_mv | AT xieguozhu carnkcellsapromisingcellularimmunotherapyforcancer AT donghan carnkcellsapromisingcellularimmunotherapyforcancer AT liangyong carnkcellsapromisingcellularimmunotherapyforcancer AT hamjamesdongjoo carnkcellsapromisingcellularimmunotherapyforcancer AT rizwanromee carnkcellsapromisingcellularimmunotherapyforcancer AT chenjianzhu carnkcellsapromisingcellularimmunotherapyforcancer |